Bander, Neil H.

Publications

Sort by

Co-Author Network

selected publications

α-Labeling of J591, an Antibody Targeting Prostate-Specific Membrane Antigen: The Technique and Considerations from the First Dedicated Production Lab at an Academic Institution in the United States. Journal of nuclear medicine technology. 2023 Academic Article GET IT
Response to RL-225Ac in prostate cancer: Effect of prior treatment with RL-177Lu: A systematic review of the literature. The Prostate. 2023 Review GET IT
Times cited: 1
Reversible epigenetic alterations mediate PSMA expression heterogeneity in advanced metastatic prostate cancer. JCI insight. 2023 Academic Article GET IT
Times cited: 1
Correction to: [⁸⁹Zr]Zr‑huJ591 immuno‑PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European journal of nuclear medicine and molecular imaging. 2022 Article GET IT
Pilot study of the diagnostic utility of ⁸⁹ Zr-df-IAB2M and ⁶⁸ Ga-PSMA-11 PET imaging and multiparametric MRI in localized prostate cancer. The Prostate. 2022 Academic Article GET IT
Times cited: 6
Prostate-Specific Membrane Antigen Positron Emission Tomography and the New Algorithm for Patients With Prostate Cancer Prior to Prostatectomy. JAMA oncology. 2021 Comment GET IT
Times cited: 2
[⁸⁹Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma. European journal of nuclear medicine and molecular imaging. 2021 Academic Article GET IT
Times cited: 4
Emerging Prostate-specific Membrane Antigen-based Therapeutics: Small Molecules, Antibodies, and Beyond. European urology focus. 2021 Review GET IT
Times cited: 8
Prostate-Specific Membrane Antigen Uptake and Survival in Metastatic Castration-Resistant Prostate Cancer. Frontiers in oncology. 2021 Academic Article GET IT
Times cited: 198
A simple strategy to reduce the salivary gland and kidney uptake of PSMA-targeting small molecule radiopharmaceuticals. European journal of nuclear medicine and molecular imaging. 2021 Academic Article GET IT
Times cited: 22
Imaging expression of prostate-specific membrane antigen and response to PSMA-targeted β-emitting radionuclide therapies in metastatic castration-resistant prostate cancer. The Prostate. 2021 Academic Article GET IT
Times cited: 7
Folate hydrolase-1 (FOLH1) is a novel target for antibody-based brachytherapy in Merkel cell carcinoma. Skin health and disease. 2020 Academic Article GET IT
Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting. The Prostate. 2020 Review GET IT
Times cited: 15
Phase I trial of docetaxel plus lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷Lu-J591) for metastatic castration-resistant prostate cancer. Urologic oncology. 2020 Academic Article GET IT
Times cited: 20
Prostatic irradiation-induced sexual dysfunction: A review and multidisciplinary guide to management in the radical radiotherapy era (Part II on Urological Management). Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. 2020 Review GET IT
Times cited: 4
Prostatic irradiation-induced sexual dysfunction: a review and multidisciplinary guide to management in the radical radiotherapy era (Part I defining the organ at risk for sexual toxicities). Reports of practical oncology and radiotherapy : journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology. 2020 Review GET IT
Times cited: 10
Pilot Study of Hyperfractionated Dosing of Lutetium-177-Labeled Antiprostate-Specific Membrane Antigen Monoclonal Antibody J591 (¹⁷⁷ Lu-J591) for Metastatic Castration-Resistant Prostate Cancer. The oncologist. 2020 Academic Article GET IT
Times cited: 24
Phase 1/2 study of fractionated dose lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 (¹⁷⁷ Lu-J591) for metastatic castration-resistant prostate cancer. Cancer. 2019 Academic Article GET IT
Times cited: 73
Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-Drug Conjugate Targeting PSMA, in Preclinical Models of Prostate Cancer. Molecular cancer therapeutics. 2018 Academic Article GET IT
Times cited: 28
Anti-PSMA/CD3 Bispecific Antibody Delivery and Antitumor Activity Using a Polymeric Depot Formulation. Molecular cancer therapeutics. 2018 Academic Article GET IT
Times cited: 29
Meeting report from the Prostate Cancer Foundation PSMA-directed radionuclide scientific working group. The Prostate. 2018 Review GET IT
Times cited: 30
Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy. Applied immunohistochemistry & molecular morphology : AIMM. 2017 Academic Article GET IT
Times cited: 31
The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. Journal for immunotherapy of cancer. 2016 Academic Article GET IT
Times cited: 71
Phase 1/2 multiple ascending dose trial of the prostate-specific membrane antigen-targeted antibody drug conjugate MLN2704 in metastatic castration-resistant prostate cancer. Urologic oncology. 2016 Academic Article GET IT
Times cited: 36
Induction of PSMA and Internalization of an Anti-PSMA mAb in the Vascular Compartment. Molecular cancer research : MCR. 2016 Academic Article GET IT
Times cited: 22
Targeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modeling. EJNMMI research. 2016 Academic Article GET IT
Times cited: 56
Prostate-Specific Membrane Antigen Is a Potential Antiangiogenic Target in Adrenocortical Carcinoma. The Journal of clinical endocrinology and metabolism. 2016 Academic Article GET IT
Times cited: 14
Radioimmunotherapy of Metastatic Prostate Cancer with ¹⁷⁷Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Current radiopharmaceuticals. 2016 Review GET IT
Times cited: 54
A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2015 Academic Article GET IT
Times cited: 148
Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors. EJNMMI research. 2015 Academic Article GET IT
Times cited: 111
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy. OncoTargets and therapy. 2014 Review GET IT
Times cited: 53
The oestrogen receptor alpha-regulated lncRNA NEAT1 is a critical modulator of prostate cancer. Nature communications. 2014 Academic Article GET IT
Times cited: 494
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. European journal of nuclear medicine and molecular imaging. 2014 Academic Article GET IT
Times cited: 112
In vitro method to observe E-selectin-mediated interactions between prostate circulating tumor cells derived from patients and human endothelial cells. Journal of visualized experiments : JoVE. 2014 Academic Article GET IT
Times cited: 2
Circulating tumor cells from prostate cancer patients interact with E-selectin under physiologic blood flow. PloS one. 2013 Academic Article GET IT
Times cited: 34
Prostate-specific membrane antigen expression in tumor-associated vasculature of breast cancers. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica. 2013 Academic Article GET IT
Times cited: 82
Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system. Biomedical microdevices. 2013 Academic Article GET IT
Times cited: 49
A prospective pilot study of (89)Zr-J591/prostate specific membrane antigen positron emission tomography in men with localized prostate cancer undergoing radical prostatectomy. The Journal of urology. 2013 Academic Article GET IT
Times cited: 64
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture. Electrophoresis. 2013 Academic Article GET IT
Times cited: 19
Bone marrow recovery and subsequent chemotherapy following radiolabeled anti-prostate-specific membrane antigen monoclonal antibody j591 in men with metastatic castration-resistant prostate cancer. Frontiers in oncology. 2013 Academic Article GET IT
Times cited: 21
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clinical cancer research : an official journal of the American Association for Cancer Research. 2013 Academic Article GET IT
Times cited: 321
Antibody-drug conjugate target selection: critical factors. Methods in molecular biology (Clifton, N.J.). 2013 Review GET IT
Times cited: 40
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer discovery. 2012 Academic Article GET IT
Times cited: 244
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (London, England). 2012 Academic Article GET IT
Times cited: 63
Antibody-drug conjugate technology development for hematologic disorders. Clinical advances in hematology & oncology : H&O. 2012 Academic Article GET IT
Times cited: 2
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PloS one. 2012 Academic Article GET IT
Times cited: 181
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Science translational medicine. 2012 Academic Article GET IT
Times cited: 910
Immunocapture of prostate cancer cells by use of anti-PSMA antibodies in microdevices. Biomedical microdevices. 2012 Academic Article GET IT
Times cited: 38
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc. 2012 Academic Article GET IT
Times cited: 56
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Archives of pathology & laboratory medicine. 2011 Academic Article GET IT
Times cited: 80
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2011 Academic Article GET IT
Times cited: 50
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer research. 2011 Academic Article GET IT
Times cited: 356
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjugate chemistry. 2011 Academic Article GET IT
Times cited: 117
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proceedings of the National Academy of Sciences of the United States of America. 2011 Academic Article GET IT
Times cited: 232
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. The Prostate. 2010 Academic Article GET IT
Times cited: 52
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2010 Academic Article GET IT
Times cited: 341
ChemoRad nanoparticles: a novel multifunctional nanoparticle platform for targeted delivery of concurrent chemoradiation. Nanomedicine (London, England). 2010 Academic Article GET IT
Times cited: 99
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer. 2010 Academic Article GET IT
Times cited: 122
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab on a chip. 2009 Academic Article GET IT
Times cited: 317
Docetaxel down-regulates the expression of androgen receptor and prostate-specific antigen but not prostate-specific membrane antigen in prostate cancer cell lines: implications for PSA surrogacy. The Prostate. 2009 Academic Article GET IT
Times cited: 80
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Human pathology. 2009 Academic Article GET IT
Times cited: 180
Editorial comment. The Journal of urology. 2009 Editorial Article GET IT
Times cited: 1
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem. 2008 Academic Article GET IT
Times cited: 266
Interaction of prostate specific membrane antigen with clathrin and the adaptor protein complex-2. International journal of oncology. 2007 Academic Article GET IT
Times cited: 25
Active and passive immunotherapy: vaccines and antibodies. BJU international. 2007 Review GET IT
Times cited: 6
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2007 Academic Article GET IT
Times cited: 198
Differing effects of microtubule depolymerizing and stabilizing chemotherapeutic agents on t-SNARE-mediated apical targeting of prostate-specific membrane antigen. Molecular cancer therapeutics. 2006 Academic Article GET IT
Times cited: 5
Technology insight: monoclonal antibody imaging of prostate cancer. Nature clinical practice. Urology. 2006 Review GET IT
Times cited: 111
Clinical utility of radiolabeled monoclonal antibodies in prostate cancer. Clinical genitourinary cancer. 2006 Review GET IT
Times cited: 23
Antibody-based therapeutics: focus on prostate cancer. Cancer metastasis reviews. 2005 Review GET IT
Times cited: 39
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clinical cancer research : an official journal of the American Association for Cancer Research. 2005 Academic Article GET IT
Times cited: 112
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Molecular cancer therapeutics. 2005 Academic Article GET IT
Times cited: 25
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 83
Phase I trial of 177lutetium-labeled J591, a monoclonal antibody to prostate-specific membrane antigen, in patients with androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2005 Academic Article GET IT
Times cited: 428
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu?. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2005 Academic Article GET IT
Times cited: 127
Determination of immunoreactive fraction of radiolabeled monoclonal antibodies: what is an appropriate method?. Cancer biotherapy & radiopharmaceuticals. 2004 Academic Article GET IT
Times cited: 29
Downregulation of Bcl-2 sensitises interferon-resistant renal cancer cells to Fas. British journal of cancer. 2004 Academic Article GET IT
Times cited: 24
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2004 Academic Article GET IT
Times cited: 292
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. The Prostate. 2004 Academic Article GET IT
Times cited: 56
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjugate chemistry. 2004 Academic Article GET IT
Times cited: 237
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. The Journal of urology. 2003 Review GET IT
Times cited: 122
Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen. The Journal of urology. 2003 Academic Article GET IT
Times cited: 207
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Molecular biology of the cell. 2003 Academic Article GET IT
Times cited: 165
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Seminars in oncology. 2003 Review GET IT
Times cited: 136
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer research. 2003 Academic Article GET IT
Times cited: 71
Polarity of prostate specific membrane antigen, prostate stem cell antigen, and prostate specific antigen in prostate tissue and in a cultured epithelial cell line. The Prostate. 2003 Academic Article GET IT
Times cited: 21
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. Journal of nuclear medicine : official publication, Society of Nuclear Medicine. 2003 Academic Article GET IT
Times cited: 164
In vitro and preclinical targeted alpha therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate cancer and prostatic diseases. 2002 Academic Article GET IT
Times cited: 79
Tumor therapy with targeted atomic nanogenerators. Science (New York, N.Y.). 2001 Academic Article GET IT
Times cited: 396
Society of Urologic Oncology Biotechnology Forum: new approaches and targets for advanced prostate cancer. The Journal of urology. 2001 Review GET IT
Times cited: 8
The T cell death knell: immune-mediated tumor death in renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 2001 Academic Article GET IT
Times cited: 16
Response of LNCaP spheroids after treatment with an alpha-particle emitter (213Bi)-labeled anti-prostate-specific membrane antigen antibody (J591). Cancer research. 2001 Academic Article GET IT
Times cited: 93
Na,K-ATPase beta-subunit is required for epithelial polarization, suppression of invasion, and cell motility. Molecular biology of the cell. 2001 Academic Article GET IT
Times cited: 170
An alpha-particle emitting antibody ([213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer research. 2000 Academic Article GET IT
Times cited: 230
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer research. 2000 Academic Article GET IT
Times cited: 187
Detection of prostate-specific membrane antigen expressing cells in blood obtained from renal cancer patients: a potential biomarker of vascular invasion. Cancer detection and prevention. 2000 Academic Article GET IT
Times cited: 9
Overview of evolving strategies incorporating prostate-specific membrane antigen as target for therapy. Molecular urology. 2000 Review GET IT
Times cited: 25
Antigens recognized by autologous antibody in patients with renal-cell carcinoma. International journal of cancer. 1999 Academic Article GET IT
Times cited: 164
Cytotoxicity of adenoviral-mediated cytosine deaminase plus 5-fluorocytosine gene therapy is superior to thymidine kinase plus acyclovir in a human renal cell carcinoma model. The Journal of urology. 1999 Academic Article GET IT
Times cited: 33
Monoclonal antibodies: will they become an integral part of the evaluation and treatment of prostate cancer--focus on prostate-specific membrane antigen?. Current opinion in urology. 1999 Review GET IT
Times cited: 12
Reduced expression of beta-subunit of Na,K-ATPase in human clear-cell renal cell carcinoma. The Journal of urology. 1999 Academic Article GET IT
Times cited: 75
The detection of renal carcinoma cells in the peripheral blood with an enhanced reverse transcriptase-polymerase chain reaction assay for MN/CA9. Cancer. 1999 Academic Article GET IT
Times cited: 70
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer research. 1999 Academic Article GET IT
Times cited: 704
Dead or dying: necrosis versus apoptosis in caspase-deficient human renal cell carcinoma. Cancer research. 1999 Academic Article GET IT
Times cited: 81
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia (New York, N.Y.). 1999 Academic Article GET IT
Times cited: 199
Mechanisms of apoptosis in T cells from patients with renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1999 Academic Article GET IT
Times cited: 129
Prostate-specific membrane antigen (PSMA)-specific monoclonal antibodies in the treatment of prostate and other cancers. Cancer metastasis reviews. 1999 Review GET IT
Times cited: 63
Mouse-human chimeric anti-epidermal growth factor receptor antibody C225 inhibits the growth of human renal cell carcinoma xenografts in nude mice. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 140
Phase I/II radioimmunotherapy trial with iodine-131-labeled monoclonal antibody G250 in metastatic renal cell carcinoma. Clinical cancer research : an official journal of the American Association for Cancer Research. 1998 Academic Article GET IT
Times cited: 148
Constitutive and antibody-induced internalization of prostate-specific membrane antigen. Cancer research. 1998 Academic Article GET IT
Times cited: 374
Aminopeptidase A expression and enzymatic activity in primary human renal cancers. International journal of oncology. 1998 Academic Article GET IT
Times cited: 21
MHC class I and II expression in prostate carcinoma and modulation by interferon-alpha and -gamma. The Prostate. 1997 Academic Article GET IT
Times cited: 78
A multicenter trial evaluation of the fibrin/fibrinogen degradation products test for detection and monitoring of bladder cancer. The Journal of urology. 1997 Academic Article GET IT
Times cited: 113
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer research. 1997 Academic Article GET IT
Times cited: 469
Expression of the tumor-associated gene MN: a potential biomarker for human renal cell carcinoma. Cancer research. 1997 Academic Article GET IT
Times cited: 114
Summary of immunohistologic dissection of the human kidney using monoclonal antibodies (by Neil H. Bander, MD, Carlos Cordon-Cardo, MD, PhD, Connie L. Finstad, PhD, Willet F. Whitmore, Jr, MD, E. Darracott Vaughan, Jr, MD, Herbert F. Oettgen, MD, Myron Melamed, MD, and Lloyd J. Old, MD). 1985. Seminars in urologic oncology. 1997 Academic Article GET IT
Times cited: 3
Renal-cell carcinoma. The New England journal of medicine. 1996 Review GET IT
Times cited: 1590
Major histocompatibility complex class I and class II expression in renal cell carcinoma and modulation by interferon gamma. The Journal of urology. 1996 Academic Article GET IT
Times cited: 46
Cytotoxicity of gallium nitrate in vitro using bladder cancer cells. International journal of urology : official journal of the Japanese Urological Association. 1995 Academic Article GET IT
Times cited: 4
Reactivities of mouse monoclonal antibody K2.7 to renal cancers in complement dependent cytotoxicity and antibody dependent cell-mediated cytotoxicity. The Journal of urology. 1995 Academic Article GET IT
Current status of monoclonal antibodies for imaging and therapy of prostate cancer. Seminars in oncology. 1994 Review GET IT
Times cited: 13
Mutations of the VHL tumour suppressor gene in renal carcinoma. Nature genetics. 1994 Academic Article GET IT
Times cited: 1519
Region-specific methylation of the parathyroid hormone-related peptide gene determines its expression in human renal carcinoma cell lines. The Journal of biological chemistry. 1993 Academic Article GET IT
Times cited: 24
Interleukin-10 production by human carcinoma cell lines and its relationship to interleukin-6 expression. International journal of cancer. 1993 Academic Article GET IT
Times cited: 234
Molecular cloning of the human kidney differentiation antigen gp160: human aminopeptidase A. Proceedings of the National Academy of Sciences of the United States of America. 1993 Academic Article GET IT
Times cited: 110
Antibody localization in human renal cell carcinoma: a phase I study of monoclonal antibody G250. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1993 Academic Article GET IT
Times cited: 168
High IL-6 levels in ascitic fluid correlate with reactive thrombocytosis in patients with epithelial ovarian cancer. British journal of haematology. 1993 Academic Article GET IT
Times cited: 101
A pilot study of immunization with interleukin-2 secreting allogeneic HLA-A2 matched renal cell carcinoma cells in patients with advanced renal cell carcinoma. Human gene therapy. 1992 Academic Article GET IT
Times cited: 27
Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer research. 1992 Academic Article GET IT
Times cited: 110
Initial results with slightly modified Kock pouch. Urology. 1991 Academic Article GET IT
Times cited: 7
Establishment and characterization of human renal cancer and normal kidney cell lines. Cancer research. 1990 Academic Article GET IT
Times cited: 151
Antiproliferative and antitumor effects of alpha-interferon in renal cell carcinomas: correlation with the expression of a kidney-associated differentiation glycoprotein. Cancer research. 1990 Academic Article GET IT
Times cited: 79
Simultaneous pulmonary and renal malignancy. 1990 GET IT
Times cited: 8
Heteroconjugate antibody-directed killing of autologous human renal carcinoma cells by in vitro-activated lymphocytes. Journal of immunology (Baltimore, Md. : 1950). 1990 Academic Article GET IT
Times cited: 20
[Biological markers in renal cell carcinoma]. Der Urologe. Ausg. A. 1990 Review GET IT
Times cited: 1
Immunodiagnosis of renal cell carcinoma. Immunology series. 1990 Review GET IT
Times cited: 1
Infrequent ras oncogene point mutations in renal cell carcinoma. The Journal of urology. 1990 Academic Article GET IT
Times cited: 65
Monoclonal antibodies to renal cancer antigens. European urology. 1990 Review GET IT
Times cited: 1
Recent diagnostic modalities for bladder cancer. Immunology series. 1990 Review GET IT
Times cited: 1
Somatic cell genetic analysis of human cell surface antigens 5.1H11 and F35/9 (gp45). Genomics. 1990 Academic Article GET IT
Times cited: 2
Ureteral stent for nonrefluxing, continent urinary diversions. Reduces complications and hospitalization for patients. Urology. 1990 Academic Article GET IT
Times cited: 2
Methotrexate, vinblastine, doxorubicin, and cisplatin for advanced transitional cell carcinoma of the urothelium. Efficacy and patterns of response and relapse. Cancer. 1989 Academic Article GET IT
Times cited: 643
A phase II clinical trial of adoptive immunotherapy for advanced renal cell carcinoma using mitogen-activated autologous leukocytes and continuous infusion interleukin-2. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 1989 Academic Article GET IT
Times cited: 28
Analysis of a mouse monoclonal antibody that reacts with a specific region of the human proximal tubule and subsets renal cell carcinomas. Cancer research. 1989 Academic Article GET IT
Times cited: 50
Kidney-derived cell lines. Seminars in urology. 1989 Review GET IT
Times cited: 5
Monoclonal antibodies to renal cancer antigens. Seminars in urology. 1989 Review GET IT
Times cited: 8
Transformation of human kidney proximal tubule cells by ras-containing retroviruses. Implications for tumor progression. The Journal of experimental medicine. 1989 Academic Article GET IT
Times cited: 12
Failure of cytotoxic chemotherapy, 1983-1988, and the emerging role of monoclonal antibodies for renal cancer. Urologia internationalis. 1989 Review GET IT
Times cited: 39
Identification of transcripts encoding a parathyroid hormone-like peptide in messenger RNAs from a variety of human and animal tumors associated with humoral hypercalcemia of malignancy. The Journal of clinical investigation. 1988 Academic Article GET IT
Times cited: 118
In vitro adenylate cyclase-stimulating activity predicts the occurrence of humoral hypercalcemia of malignancy in nude mice. The Journal of clinical investigation. 1988 Academic Article GET IT
Times cited: 22
M-VAC (methotrexate, vinblastine, doxorubicin and cisplatin) for advanced transitional cell carcinoma of the urothelium. The Journal of urology. 1988 Academic Article GET IT
Times cited: 442
Chemotherapeutic management of invasive bladder carcinoma. European urology. 1988 Academic Article GET IT
Times cited: 2
Identification of a cDNA encoding a parathyroid hormone-like peptide from a human tumor associated with humoral hypercalcemia of malignancy. Proceedings of the National Academy of Sciences of the United States of America. 1988 Academic Article GET IT
Times cited: 384
DNA-mediated gene transfer of a human cell surface 170-kilodalton glycoprotein. Evidence for association with an endogenous murine protein. The Journal of biological chemistry. 1987 Academic Article GET IT
Times cited: 8
Newer diagnostic techniques for bladder cancer. The Urologic clinics of North America. 1987 Review GET IT
Times cited: 8
Monoclonal antibodies in urologic oncology. Cancer. 1987 Academic Article GET IT
Times cited: 22
Monoclonal antibodies: state of the art. The Journal of urology. 1987 Review GET IT
Times cited: 16
Immunoanatomic distribution of cytostructural and tissue-associated antigens in the human urinary tract. The American journal of pathology. 1987 Academic Article GET IT
Times cited: 54
Diagnosis of renal proximal tubular injury by urinary immunoassay for a proximal tubular antigen, the adenosine deaminase binding protein. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 1987 Academic Article GET IT
Times cited: 9
Immunoanatomic distribution of blood group antigens in the human urinary tract. Influence of secretor status. Laboratory investigation; a journal of technical methods and pathology. 1986 Academic Article GET IT
Times cited: 60
Diagnosis of tubular injury in renal transplant patients by a urinary assay for a proximal tubular antigen, the adenosine-deaminase-binding protein. Transplantation. 1986 Academic Article GET IT
Times cited: 24
Phase I/II trial of intravesical methotrexate for superficial bladder tumors. Cancer chemotherapy and pharmacology. 1986 Academic Article GET IT
Times cited: 1
Human renal cell carcinoma xenograft: morphology, growth and chemosensitivities. The Journal of urology. 1985 Academic Article GET IT
Times cited: 2
Specificity analysis of mouse monoclonal antibodies defining cell surface antigens of human renal cancer. Proceedings of the National Academy of Sciences of the United States of America. 1985 Academic Article GET IT
Times cited: 74
Immunohistologic dissection of the human kidney using monoclonal antibodies. The Journal of urology. 1985 Academic Article GET IT
Times cited: 35
Immunoanatomic dissection of the human urinary tract by monoclonal antibodies. The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society. 1984 Academic Article GET IT
Times cited: 54
Comparison of antigen expression of human renal cancers in vivo and in vitro. Cancer. 1984 Academic Article GET IT
Times cited: 12
Study of the normal human kidney and kidney cancer with monoclonal antibodies. Uremia investigation. 1984 Academic Article GET IT
Times cited: 4
Re: in vivo and in vitro effects of xenogeneic immune ribonucleic acid in patients with advanced renal cell carcinoma: a phase I study. The Journal of urology. 1982 Letter GET IT
Effects in the rat of intradermal injection of purified proteinases from streptococcus and Serratia marcescens. Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine (New York, N.Y.). 1975 Academic Article GET IT
Times cited: 13

more ...

less ...

Research

Sort by

Co-investigator Network

Funding awarded

Heating cold prostate tumors with PSMA-targeted alpha therapy and pembrolizumab awarded by United States Department of Defense Co-Investigator 2020 - 2024

Weill Cornell Medicine (WCM) SPORE in Prostate Cancer awarded by National Cancer Institute Key Personnel 2017 - 2023

more ...

less ...

Background

education and training

M.D., University of Connecticut School of Medicine 1974
B.A., The Johns Hopkins University 1969

Contact

full name

Neil H. Bander

primary email

nhbander@med.cornell.edu

VIVO Weill Cornell Medical College

Neil H. Bander Professor Emeritus of Urology

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email

Phone

Publications

selected publications

Research

Funding awarded

Background

education and training

Contact

full name

primary email